期刊文献+

二氢嘧啶脱氢酶及其基因检测与指导化疗的研究进展

Research Progress in Dihydropyrimidine Dehydrogenase Gene Detection and Guiding Chemotherapy
原文传递
导出
摘要 药物疗效和毒性存在个体差异是临床常见的现象,癌症患者接受化疗时更为明显,一直受到临床医生关注。不少临床因素影响人体对药物的反应,但是随着分子生物学、分子遗传学与分子药理学,特别是基因组学的发展,人们逐渐认识到不同个体对同一药物的不同反应大多源于基因的多态性。文章总结二氢嘧啶脱氢酶及其基因单核苷酸多态性的研究进展,理解两者的关系有利于更好地实现5-氟尿嘧啶个体化化疗。
出处 《中国肿瘤》 CAS 2009年第12期1003-1007,共5页 China Cancer
基金 安徽省自然科学基金(070413256X) 2008年安徽省临床医学应用技术项目(2008A054)
  • 相关文献

参考文献7

  • 1何义富,王风华,张星,李苏,李志铭,李宇红,张东生,季楚舒,胡冰,姜文奇.肿瘤患者二氢嘧啶脱氢酶基因单核苷酸多态性分析[J].中国肿瘤,2008,17(12):1044-1047. 被引量:5
  • 2贾莉,李建华,蔡剑平,郭健.汉族人群中二氢嘧啶脱氢酶基因多态性的初步研究[J].中日友好医院学报,2005,19(4):202-204. 被引量:13
  • 3Hong Zhang,You-Ming Li,Hao Zhang,Xi Jin. DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU[J] 2007,Medical Oncology(2):251~258
  • 4Kotaro Miyake,Satoru Imura,Tomoharu Yoshizumi,Tetsuya Ikemoto,Yuji Morine,Mitsuo Shimada. Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer[J] 2007,International Journal of Clinical Oncology(2):111~119
  • 5Hui-Hua Hsiao,Ming-Yu Yang,Jan-Gowth Chang,Yi-Chang Liu,Ta-Chih Liu,Chao-Sung Chang,Tyen-Po Chen,Sheng-Fung Lin. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwan Residents population[J] 2004,Cancer Chemotherapy and Pharmacology(5):445~451
  • 6Kenji Omura. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines[J] 2003,International Journal of Clinical Oncology(3):132~138
  • 7A. Di Paolo,R. Danesi,A. Falcone,L. Cionini,F. Vannozzi,G. Masi,G. Allegrini,E. Mini,G. Bocci,P. F. Conte,M. Del Tacca. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients[J] 2001,Annals of Oncology(9):1301~1306

二级参考文献28

  • 1贾莉,李建华,蔡剑平,郭健.汉族人群中二氢嘧啶脱氢酶基因多态性的初步研究[J].中日友好医院学报,2005,19(4):202-204. 被引量:13
  • 2Milano G, Etience MC. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil[J]. Anticancer Res, 1994, 14(6A) : 2295-2297.
  • 3Harry BE, Song R, Soong S, et al. Ralationship between dihydropyrlmidine dehydrogenase activity and plasma 5- fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion [J]. Cancer Res, 1990, 50(1): 197-201.
  • 4Johnson MR, Wang K, Tilhnanns S, et al. Strctural organization of the human dihdropyrimidine deghydrogenase gene[J]. Cancer Res, 1997, 57(9): 1660-1663.
  • 5Bertilsson L. Geogrophical/interracial difference in polymorphic drug oxidation[J]. Clin Pharmacokinet, 1995, 29 (3): 192-209.
  • 6Wei X, McLeod HL, McMurrough J, et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity[J]. J Clin Invest, 1996, 98(3): 610-615.
  • 7van Kuilenburg AB.Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil[J]. Eur J Cancer, 2004, 40(7) : 939-950.
  • 8Hsiao HH, Yang MY, Chang JG, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwan Residents population[J].Cancer Chemother Pharmacol,2004,53(5):445-451.
  • 9Mcleod HL, Collie-Duguid ESR, Vreken P, et al. Nomenclature for human DPYD alleles [J]. Pharmaeogenetics, 1998, 8(6) :455-459.
  • 10Ridge SA, Sludden J, Brown O, et al. Dihydropyrimidine dehydrogenase pharmaeogeneties in Caucasian subjects[J]. Br J Clin Pharmacol, 1998, 46(2): 151-156.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部